Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Study of YLB113 vs Enbrel in Rheumatoid Arthritis
2015-002809-12Phase 3Completed
- Sponsor
- YL Biologics Limited
- Start
- Aug 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ylb113 in rheumatoid arthritis (RA) (2 arms), sponsored by YL Biologics Limited. Primary endpoint: ACR20 response at Week 12. Started Aug 2015; status: completed.
02
Drugs
ylb113
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-002809-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002809-12.